Innovent Biologics
Tracked across 2 events · 15 articles · First seen May 08, 2026 · Last active Jun 01, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Tech
Innovent Biologics announced updated long-term follow-up data from its Phase 1 PoC clinical study of IBI363 (PD-1/IL-2 bispecific fusion protein) in advanced immunotherapy-resistant non-small cell lung cancer (NSCLC) at the 2026 American Society of Clinical…
Impact: Innovent Biologics is the developer and co-commercializer of IBI363, and the positive long-term clinical trial results enhance its product pipeline and market position in oncology. The company's stock performance is likely to benefit from these favorable outcomes and the progression to global Phase 3 studies.
May 21, 2026 · 9 articles
90
Innovent Biologics presented updated data American Society of Clinical OncologyIBI363 Shows Survival...
80
Innovent Biologics entered global Phase 3 studyIBI363 Shows Survival...
70
Innovent Biologics co-developed IBI363 Takeda Pharmaceutical CompanyIBI363 Shows Survival...
60
United States — Food and Drug Administration granted Fast Track Designations Innovent BiologicsIBI363 Shows Survival...
60
China — National Medical Products Administration granted Breakthrough Therapy Designations Innovent BiologicsIBI363 Shows Survival...
NEWSDESK
Track Innovent Biologics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard